Novartis iptacopan meets primary endpoint in new rare kidney disease trial

Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy (IgAN)Ad hoc announcement pursuant to Art. 53 LRPhase III APPLAUSE-IgAN study met its pre-specified interim analysis primary endpoint, demo...

Related Keywords

United States ,Shreeram Aradhye ,Novartis Pharmaceuticals ,European Medicines Agency ,Exchange Commission ,Twitter ,Novartis Biomedical Research ,Novartis ,Chief Medical Officer ,Chinook Therapeutics ,About Iga ,Therapy Designation ,Natl Acad ,Alternative Complement Pathway With Iptacopan ,Treat Iga Nephropathy ,Kidney Int ,Emerging Role ,Complement Proteins ,Rev Dis ,Accessed September ,Proteinuria Improves Prognosis ,Practice Guideline ,Current State ,Clinical Trials ,Parallel Group ,Primary Iga Nephropathy ,Clinj Am Soc ,Iga Nephropathy ,Future Management ,Adv Chronic Kidney ,Rare Pediatric Disease Designation ,